{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:03:30Z","timestamp":1776485010982,"version":"3.51.2"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Non-alcoholic fatty liver disease (NAFLD) results from an excessive accumulation of fat particles that causes liver inflammation, which ultimately causes liver damage. There is still considerable uncertainty about the effects of any nutritional supplements compared to no additional intervention. This review aimed to evaluate the efficacy of <jats:italic>Allium sativum (A. sativum)<\/jats:italic>, known as garlic, in preventing and treating NAFLD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search based on a search strategy consisting of two components of \u201cNAFLD\u201d and \u201c<jats:italic>Allium sativum<\/jats:italic>\u201d in databases including PubMed, Web of Science (WoS), and SCOPUS was conducted on papers evaluating the effects of <jats:italic>A. sativum<\/jats:italic> on NAFLD treatment and prevention. We obtained studies from inception until 20 September 2022, followed by study selection and data extraction based on our eligibility criteria. Consequently, qualitative and quantitative synthesis was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our qualitative analysis reveals that <jats:italic>A. sativum<\/jats:italic> consumption is linked to the prevention of NAFLD, especially in males, although qualitative data in this study regarding the therapeutic properties of NAFLD was controversial. Our meta-analysis showed that NAFLD patients treated with <jats:italic>A. sativum<\/jats:italic> have significantly declined aminotransferase levels. That is to say, our meta-analysis revealed a lower alanine transaminase (ALT) (SMD = \u22120.580, 95%CI = \u22120.822 to \u22120.338), and aspartate transaminase (AST(SMD = \u22120.526, 95%CI = \u22120.767 to \u22120.284) in NAFLD patients treated with <jats:italic>A. sativum<\/jats:italic> compared to the placebo group. Also, pooling data from case-control studies showed that A. sativum consumption decreases the odds of being diagnosed with NAFLD by 46% (OR = 0.538, 95%CI = 0.451\u20130.625).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:italic>A. sativum<\/jats:italic> consumption is not merely associated with NAFLD prevention but also results in a considerable decline in blood aminotransferase levels in patients diagnosed with NAFLD. To put it simply, <jats:italic>A. sativum<\/jats:italic> is linked to a decline in AST and ALT, which are considered reliable biomarkers of NAFLD response to treatment. Nevertheless, <jats:italic>A. sativum<\/jats:italic> is insufficient to improve NAFLD independent of other dietary amendments and lifestyle modifications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnut.2023.1059106","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T05:40:20Z","timestamp":1675316420000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Allium sativum: A potential natural compound for NAFLD prevention and treatment"],"prefix":"10.3389","volume":"10","author":[{"given":"Parham","family":"Mardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Kargar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramina","family":"Fazeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Qorbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome.","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jgh.12271","article-title":"Characteristics and diagnosis of NAFLD\/NASH.","volume":"28","author":"Hashimoto","year":"2013","journal-title":"J Gastroenterol Hepatol."},{"key":"B4","article-title":"Controversies in the diagnosis and management of NAFLD and NASH.","volume":"10","author":"Rinella","year":"2014","journal-title":"Gastroenterol Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1756283X15611581","article-title":"Practice patterns in NAFLD and NASH: real life differs from published guidelines.","volume":"9","author":"Rinella","year":"2016","journal-title":"Ther Adv Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/tri.13001","article-title":"Cardiovascular mortality among liver transplant recipients with non-alcoholic steatohepatitis in the United States\u2014a retrospective study.","volume":"30","author":"Satapathy","year":"2017","journal-title":"Transplant Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1872-034X.2011.00824.x","article-title":"NASH: a global health problem.","volume":"41","author":"Sanyal","year":"2011","journal-title":"Hepatol Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4291\/wjgp.v8.i2.51","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk.","volume":"8","author":"Patil","year":"2017","journal-title":"World J Gastrointest Pathophysiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Non-alcoholic fatty liver disease: a systematic review.","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/MED.0000000000000464","article-title":"Dyslipidemia in non-alcoholic fatty liver disease.","volume":"26","author":"Amor","year":"2019","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"key":"B11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cld.2009.07.006","article-title":"Lifestyle modification as the primary treatment of NASH.","volume":"13","author":"Neuschwander-Tetri","year":"2009","journal-title":"Clin Liver Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of non-alcoholic steatohepatitis.","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options.","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.cgh.2021.03.005","article-title":"Treatment candidacy for pharmacologic therapies for NASH.","volume":"20","author":"Rowe","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.nut.2014.01.016","article-title":"Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.","volume":"30","author":"Ji","year":"2014","journal-title":"Nutrition."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6040086","article-title":"The role of vitamin E in the treatment of NAFLD.","volume":"6","author":"Perumpail","year":"2018","journal-title":"Diseases."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for non-alcoholic fatty liver disease.","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.apsb.2019.11.017","article-title":"Herbal drug discovery for the treatment of non-alcoholic fatty liver disease.","volume":"10","author":"Yan","year":"2020","journal-title":"Acta Pharm Sin B."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/648308","article-title":"Herbal medicines for the treatment of non-alcoholic steatohepatitis: current scenario and future prospects.","volume":"2014","author":"Jadeja","year":"2014","journal-title":"Evid Based Complement Alternat Med."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00601","article-title":"Herbal medicine in the treatment of non-alcoholic fatty liver diseases-efficacy, action mechanism, and clinical application.","volume":"11","author":"Xu","year":"2020","journal-title":"Front Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11901-020-00558-2","article-title":"Herbal medicines for the treatment of nonalcoholic steatohepatitis.","volume":"20","author":"Sandhu","year":"2021","journal-title":"Curr Hepatol Rep."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.hermed.2019.100292","article-title":"Garlic (Allium sativum L.) in the management of hypertension and dyslipidemia\u2013A systematic review.","volume":"19","author":"Chan","year":"2020","journal-title":"J Herb Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3746\/jfn.2009.14.1.001","article-title":"Effect of garlic and aged black garlic on hyperglycemia and dyslipidemia in animal model of type 2 diabetes mellitus.","volume":"14","author":"Seo","year":"2009","journal-title":"Prev Nutr Food Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1007\/s00394-021-02482-7","article-title":"Types of garlic and their anticancer and antioxidant activity: a review of the epidemiologic and experimental evidence.","volume":"60","author":"Farhat","year":"2021","journal-title":"Eur J Nutr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0255","DOI":"10.1097\/MD.0000000000010255","article-title":"Anti-hyperlipidemia of garlic by reducing the level of total cholesterol and low-density lipoprotein: a meta-analysis.","volume":"97","author":"Sun","year":"2018","journal-title":"Medicine."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40618-015-0313-8","article-title":"A review on the effects of Allium sativum (Garlic) in metabolic syndrome.","volume":"38","author":"Hosseini","year":"2015","journal-title":"J Endocrinol Invest."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1002\/ptr.7146","article-title":"Effects of garlic powder supplementation on metabolic syndrome components, insulin resistance, fatty liver index, and appetite in subjects with metabolic syndrome: a randomized clinical trial.","volume":"35","author":"Sangouni","year":"2021","journal-title":"Phytother Res."},{"key":"B28","first-page":"589","article-title":"Antioxidant properties of raw garlic (Allium sativum) extract.","volume":"19","author":"Rahman","year":"2012","journal-title":"Int Food Res J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1108\/NFS-11-2019-0334","article-title":"Association of allium vegetables intake and non-alcoholic fatty liver disease risk: a case-control study.","volume":"50","author":"Emamat","year":"2020","journal-title":"Nutr Food Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00394-016-1318-6","article-title":"Efficacy and safety of fermented garlic extract on hepatic function in adults with elevated serum gamma-glutamyl transpeptidase levels: a double-blind, randomized, placebo-controlled trial.","volume":"56","author":"Kim","year":"2017","journal-title":"Eur J Nutr."},{"key":"B31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1017\/S0007114520001403","article-title":"Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial.","volume":"124","author":"Sangouni","year":"2020","journal-title":"Br J Nutr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.2147\/DMSO.S254555","article-title":"Therapeutic effects of garlic on hepatic steatosis in nonalcoholic fatty liver disease patients: a randomized clinical trial.","volume":"13","author":"Soleimani","year":"2020","journal-title":"Diabetes Metab Syndr Obes."},{"key":"B33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1530\/EJE-19-0179","article-title":"Association between dietary raw garlic intake and newly diagnosed non-alcoholic fatty liver disease: a population-based study.","volume":"181","author":"Zhang","year":"2019","journal-title":"Eur J Endocrinol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181fe7825","article-title":"PRISMA statement.","volume":"22","author":"Moher","year":"2011","journal-title":"Epidemiology."},{"key":"B35","author":"Wells","year":"2014","journal-title":"Newcastle-Ottawa Quality Assessment Scale Cohort Studies."},{"key":"B36","doi-asserted-by":"publisher","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med."},{"key":"B37","year":"2022","journal-title":"Re-expressing SMDs by Transformation to Odds Ratio."},{"key":"B38","year":"2006","journal-title":"Garlic, in Drugs and Lactation Database (LactMed)."},{"key":"B39","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4103\/0019-509X.175383","article-title":"Garlic: review of literature.","volume":"51","author":"Adaki","year":"2014","journal-title":"Indian J Cancer."},{"key":"B40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1286-4579(99)80003-3","article-title":"Antimicrobial properties of allicin from garlic.","volume":"1","author":"Ankri","year":"1999","journal-title":"Microbes Infect."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6667453","article-title":"Efficacy of oral administration of allium sativum powder \u201cGarlic Extract\u201d on Lipid profile, inflammation, and cardiovascular indices among hemodialysis patients.","volume":"2021","author":"Asgharpour","year":"2021","journal-title":"Evid Based Complement Alternat Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/1568009033333736","article-title":"Garlic [Allium sativum]: a review of its potential use as an anti-cancer agent.","volume":"3","author":"Thomson","year":"2003","journal-title":"Curr Cancer Drug Targets."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1406726","article-title":"Diallyl trisulfide suppresses oxidative stress-induced activation of hepatic stellate cells through production of hydrogen sulfide.","volume":"2017","author":"Zhang","year":"2017","journal-title":"Oxid Med Cell Longev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.jnutbio.2012.12.006","article-title":"S-allyl cysteine attenuates free fatty acid-induced lipogenesis in human HepG2 cells through activation of the AMP-activated protein kinase-dependent pathway.","volume":"24","author":"Hwang","year":"2013","journal-title":"J Nutr Biochem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00394-012-0301-0","article-title":"Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal model.","volume":"52","author":"Xiao","year":"2013","journal-title":"Eur J Nutr."},{"key":"B46","doi-asserted-by":"publisher","first-page":"5897","DOI":"10.1021\/jf500803c","article-title":"Garlic essential oil protects against obesity-triggered non-alcoholic fatty liver disease through modulation of lipid metabolism and oxidative stress.","volume":"62","author":"Lai","year":"2014","journal-title":"J Agric Food Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","article-title":"Lifestyle modification in NAFLD\/NASH: facts and figures.","volume":"1","author":"Hallsworth","year":"2019","journal-title":"JHEP Rep."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9018","article-title":"Vitamin E as an adjuvant treatment for non-alcoholic fatty liver disease in adults: a systematic review of randomized controlled trials.","volume":"12","author":"Usman","year":"2020","journal-title":"Cureus."},{"key":"B49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3350\/cmh.2015.21.4.379","article-title":"Effect of vitamin E in non-alcoholic fatty liver disease with metabolic syndrome: a propensity score-matched cohort study.","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Mol Hepatol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413424","article-title":"It is high time physicians thought of natural products for alleviating NAFLD. Is there sufficient evidence to use them?","volume":"22","author":"Tarantino","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ptr.6270","article-title":"Does turmeric\/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with non-alcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials.","volume":"33","author":"Goodarzi","year":"2019","journal-title":"Phytother Res."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2020.111092","article-title":"Impact of Silymarin in individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"83","author":"Kalopitas","year":"2021","journal-title":"Nutrition."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6030080","article-title":"Potential therapeutic benefits of herbs and supplements in patients with NAFLD.","volume":"6","author":"Perumpail","year":"2018","journal-title":"Diseases."},{"key":"B54","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.dld.2014.11.015","article-title":"Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.","volume":"47","author":"Chen","year":"2015","journal-title":"Dig Liver Dis."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2020.102635","article-title":"Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"57","author":"Wei","year":"2021","journal-title":"Complement Ther Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.15403\/jgld.2014.1121.261.ely","article-title":"Resveratrol supplementation in patients with non-alcoholic fatty liver disease: systematic review and meta-analysis.","volume":"26","author":"Elgebaly","year":"2017","journal-title":"J Gastrointestin Liver Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/ptr.6637","article-title":"Effects of green tea or green tea catechin on liver enzymes in healthy individuals and people with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized clinical trials.","volume":"34","author":"Mahmoodi","year":"2020","journal-title":"Phytother Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cld.2017.08.004","article-title":"Diagnosis and evaluation of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis, including noninvasive biomarkers and transient elastography.","volume":"22","author":"Tsai","year":"2018","journal-title":"Clin Liver Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1572-0241.2001.03553.x","article-title":"A pilot study of a thiazolidinedione, troglitazone, in non-alcoholic steatohepatitis.","volume":"96","author":"Caldwell","year":"2001","journal-title":"Am J Gastroenterol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int."},{"key":"B61","doi-asserted-by":"publisher","first-page":"427","DOI":"10.15403\/jgld-293","article-title":"Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels.","volume":"28","author":"Ulasoglu","year":"2019","journal-title":"J Gastrointestin Liver Dis."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2023.1059106\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T05:40:26Z","timestamp":1675316426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2023.1059106\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":61,"alternative-id":["10.3389\/fnut.2023.1059106"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2023.1059106","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"article-number":"1059106"}}